Robust In Vivo CRISPR Trials Will Accelerate Therapeutic Success

Published
25 Mar 25
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$33.54
67.5% undervalued intrinsic discount
14 Aug
US$10.90
Loading
1Y
-52.3%
7D
-4.9%

Author's Valuation

US$33.5

67.5% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on10 Aug 25
Fair value Decreased 9.63%

Despite a notable improvement in both future P/E and net profit margin, Intellia Therapeutics’ consensus analyst price target has been revised downward from $37.11 to $35.23. What's in the News Phase 3 HAELO trial for lonvo-z in hereditary angioedema (HAE) is ongoing, showing strong interim efficacy data; drug has received multiple regulatory designations, including FDA Orphan Drug and RMAT.

Shared on01 May 25
Fair value Increased 12%

Shared on24 Apr 25
Fair value Decreased 2.75%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 0.088%

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 105.7x to 117.8x.

Shared on09 Apr 25
Fair value Decreased 7.87%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 0.50%